Evaluation of liposomal curcumin cytochrome p450 metabolism

Author(s): Mach CM, Chen JH, Mosley SA, Kurzrock R, Smith JA


Background: Curcumin (diferuloylmethane) is a commonly used spice and nutritional supplement that has demonstrated potential anti-tumor and anti-inflammatory activity. There is limited information regarding curcumin metabolism and the potential for drug-drug interactions. The objective of this study was to characterize the hepatic metabolism of synthetic curcumin used in the liposomal curcumin formulation.

Materials and methods: High-throughput cytochrome P450 (CYP450) metabolism inhibition assays were conducted in vitro evaluating CYP450 3A4, 2C8, 2C9, and 2D6. An ex vivo model of cryopreserved human hepatocytes was used to evaluate the CYP450 metabolism induction potential of curcumin for CYP P450 3A4, 2C8/2C9, and 2D6.

Results: In the in vitro CYP450 inhibition studies, curcumin at any concentration did not inhibit CYP450 3A4 or CYP450 2D6 activity. At a curcumin concentration of 58.3 microM, 10.5% and 22.5% inhibition of CYP450 2C9 and CYP450 2C8 activity, respectively, was observed. In the ex vivo hepatocyte inductions studies, minimal to no induction of CYP450 3A4, CYP450 2C8/2C9 or CYP450 2D6 was observed. Rifampicin did not induce the metabolism of curcumin and curcumin did not induce its own metabolism.

Conclusion: There is low potential for CYP450 mediated drug interactions at physiologic serum concentrations of liposomal curcumin. Based on preliminary data, liposomal curcumin will not interact with other chemotherapy agents that are metabolized and/or eliminated via the primary drug metabolizing CYP450 pathways.

Similar Articles

Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey

Author(s): Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, et al.

Systematic review of herbs and dietary supplements for glycemic control in diabetes

Author(s): Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS

Curcumin: From ancient medicine to current clinical trials

Author(s): Hatcher H, Planalp R, Cho J, Torti FM, Torti SV

Evaluation of liposomal curcumin cytochrome p450 metabolism

Author(s): Mach CM, Chen JH, Mosley SA, Kurzrock R, Smith JA

Liquid chromatographic method for the determination of rosiglitazone in human plasma

Author(s): Kolte BL, Raut BB, Deo AA, Bagool MA, Shinde DB

Hypoglycaemic effect of Artemisia herba alba

Author(s): al-Shamaony L, al-Khazraji SM, Twaij HA

Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver

Author(s): Oetari S, Sudibyo M, Commandeur JN, Samhoedi R, Vermeulen NP

Compounds isolated from Curcuma aromatica Salisb

Author(s): Bamba Y, Yun YS, Kunugi A, Inoue H

Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products

Author(s): Appiah-Opong R, Commandeur JN, van Vugt-Lussenburg B, Vermeulen NP

Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues

Author(s): Appiah-Opong R, de Esch I, Commandeur JN, Andarini M, Vermeulen NP

Bioavailability of curcumin: problems and promises

Author(s): Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB

Curcumin therapeutic promises and bioavailability in colorectal cancer

Author(s): Shehzad A, Khan S, Shehzad O, Lee YS

Pharmacokinetics and Pharmacodynamics of Curcumin

Author(s): Sharma RA, Steward WP, Gescher AJ